Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2438]

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights...

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Racial disparities in AML: Black patients show inferior survival despite...

Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine...

Racial disparities in AML: Black patients show inferior survival despite similar cytogenetics and treatment response ( Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine, Baltimore, USA )

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Asciminib shows high molecular response, favourable safety in 2L CML-CP ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and...

Prof Jennifer Woyach - The Ohio State University, Columbus, USA

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Dr Ryan Nguyen, Rebecca Timogtimog, Carmela Timogtimog

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey ( Dr Ryan Nguyen, Rebecca Timogtimog, Carmela Timogtimog )

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

Prof Jennifer Woyach - The Ohio State University, Columbus, USA

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive...

Prof Robert Orlowski - The University of Texas MD Anderson Cancer Center...

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses ( Prof Robert Orlowski - The University of Texas MD Anderson Cancer Center, Houston, USA )

Empowering cancer care in Africa

Prof Cesaltina Ferreira Lorenzoni - Mozambican Ministry of Health, Maputo...

Empowering cancer care in Africa ( Prof Cesaltina Ferreira Lorenzoni - Mozambican Ministry of Health, Maputo, Mozambique and AORTIC President )

Pimicotinib in TGCT demonstrates durable responses and sustained functional...

Prof Hans Gelderblom - Leiden University, Leiden, Nethrlands

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement ( Prof Hans Gelderblom - Leiden University, Leiden, Nethrlands )

Latest in bladder cancer from the second half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone...

Latest in bladder cancer from the second half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Enrique Grande )

Shaping the future: advancing HR-NMIBC management beyond BCG

Dr Laura Mertens, Dr Marco Moschini and Prof Evanguelos Xylinas

Shaping the future: advancing HR-NMIBC management beyond BCG ( Dr Laura Mertens, Dr Marco Moschini and Prof Evanguelos Xylinas )

More from ecancer